Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TG Therapeutics Looks To Market Ublituximab On Convenience, Pricing In MS

Executive Summary

The drug enters the increasingly competitive space of CD20-targeting therapies for multiple sclerosis, with two agents already approved.

You may also be interested in...



Ukoniq Launch Starts TG Therapeutics' Commercial Path

A first-in-class PI3K/CK1 epsilon inhibitor, Ukoniq was approved by the US FDA for two types of lymphoma.

Incyte, TG's PI3K Inhibitors Show Safety Advantage In Indolent NHL

Neither TG's UNITY-NHL nor Incyte's CITADEL-203 study reported any fatal adverse events - a problem for which Gilead and Verastem's PI3K inhibitors carry boxed warnings.

Novartis's Ofatumumab Pursues Entrenched Competitors In MS

Novartis’s anti-CD20 MS candidate, ofatumumab, shows promise in initial findings from the ASCLEPIOS Phase III studies, but more details are needed to show how it stacks up against Sanofi’s Aubagio, and ultimately against Roche’s Ocrevus.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143471

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel